Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 4, 2025
Product Development
‘I don’t see a risk in producing data’ — Jallal’s philosophy at the heart of growing Immunocore
On The BioCentury Show, CEO Bahija Jallal discusses how the now-commercial biotech is expanding its platform to new indications
BioCentury | Apr 1, 2025
Distillery Therapeutics
Nasal anti-CD3 mAb-mediated Treg induction for traumatic brain injury
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Mar 1, 2025
Data Byte
EMA’s CHMP reaffirms its decision to back Leqembi for Alzheimer’s
Regeneron’s bispecific, Krystal’s gene therapy, and 16 label extensions also among positive opinions issued at committee’s February meeting
BioCentury | Jan 29, 2025
Deals
The NewCo boom signals China’s galloping speed of innovation
Companies founded in the West with Asian assets tell a story of China speed
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: Bispecifics poised to enter new era
Decade after first approval, bispecifics on the precipice of going mainstream
BioCentury | Dec 18, 2024
Emerging Company Profile
Adaptin: Bispecifics hitchhike into the brain using edited T cells
Duke spinout has new method to get T cell engagers across the blood-brain barrier
BioCentury | Dec 17, 2024
Deals
Candid strikes trio of T cell engager partnerships for autoimmunity
BioCentry’s Deals Report also features AbbVie acquiring Nimble, Nvelop-Chroma forming nChroma, and BMS canceling Century, Immatics deals
Items per page:
1 - 10 of 806